

Conference Program

Wednesday, September 18

- 11:00 a.m.-9:00 p.m. Registration Open**
- 1:30 p.m.-5:50 p.m. Educational Session**
- 1:30 p.m.-2:30 p.m. **Mining the TCGA**
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY
- 2:30 p.m.-3:30 p.m. **Cell lines as ovarian cancer models: Insights from molecular profiles in TCGA and CCLE**
Nikolaus Schultz, Memorial Sloan-Kettering Cancer Center, New York, NY
- 3:30 p.m.-3:50 p.m. **Break**
- 3:50 p.m.-4:50 p.m. **Biomarker development**
David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada
- 4:50 p.m.-5:50 p.m. **Bringing a drug from development to the clinic**
Carol A. Aghajanian, Memorial Sloan-Kettering Cancer Center, New York, NY
- 5:50 p.m.-7:00 p.m. Dinner on Own**
- 7:00 p.m.-9:00 p.m. Keynote Addresses**
- 7:00 p.m.-8:00 p.m. **40 years of developmental therapeutics in ovarian cancer**
Carol A. Aghajanian, Memorial Sloan-Kettering Cancer Center, New York, NY
- 8:00 p.m.-9:00 p.m. **In tumor screening for novel targets in papillary serous ovarian cancer**
David M. Livingston, Dana-Farber Cancer Institute, Boston, MA
- 9:00 p.m.-10:30 p.m. Dessert Reception**

Thursday, September 19

- 7:00 a.m.-8:00 a.m.** **Continental Breakfast**
- 8:00 a.m.-8:10 a.m.** **Welcome Note and Conference Overview**
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center,
New York, NY
- 8:10 a.m.-10:10 a.m.** **Session 1: The Origins of Ovarian Cancer**
*Session Chairperson: Robert J. Kurman, Johns Hopkins Medical
Institutes, Baltimore, MD*
- 8:10 a.m.-8:40 a.m. **A dualistic model of ovarian carcinogenesis**
Robert J. Kurman
- 8:40 a.m.-9:10 a.m. **Discovering the distal fallopian tube as the origin for high-
grade serous ovarian cancer**
Ronny I. Drapkin, Dana-Farber Cancer Institute, Boston, MA
- 9:10 a.m.-9:40 a.m. **Murine models of non-serous ovarian cancer: Effects of
mutant Trp53, Pik3ca, and Arida1a in a model of endometrioid
carcinoma based on Wnt and PI3K/Akt pathway defects**
Kathleen R. Cho, University of Michigan Medical School, Ann
Arbor, MI
- 9:40 a.m.-9:55 a.m. **Transformation of the fallopian tube secretory epithelium
leads to high-grade serous ovarian cancer in BRCA/P53
models***
Daniela Dinulescu, Brigham and Women's Hospital, Boston, MA
- 9:55 a.m.-10:10 a.m. **Cyclin E1 deregulation occurs early during fallopian tube
tumorigenesis and promotes secretory cell transformation***
Alison Karst, Dana-Farber Cancer Institute, Boston, MA
- 10:10 a.m.-10:30 a.m.** **Break**

*Short talks from proffered papers

- 10:30 a.m.-12:30 p.m.** **Session 2: Genomic Classification of Ovarian Cancer**
*Session Chairperson: James D. Brenton, Cancer Research UK
Cambridge Research Institute, Cambridge, United Kingdom*
- 10:30 a.m.-11:00 a.m. **Determinants of clinical outcome in ovarian cancer**
David D. Bowtell, Peter MacCallum Cancer Centre, Melbourne,
Australia
- 11:00 a.m.-11:30 a.m. **Discovering drivers in rare ovarian cancer subtypes**
David G. Huntsman, BC Cancer Foundation, Vancouver, BC,
Canada
- 11:30 a.m.-12:00 p.m. **Pathway-directed therapy**
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New
York, NY
- 12:00 p.m.-12:15 p.m. **Oxidants and antioxidants in the follicular fluid in initiation of
fimbriae carcinogenesis***
Hsuan-Shun Huang, Cervical Cancer Prevention Center, Tzu Chi
University, Hualien, Taiwan
- 12:15 p.m.-12:30 p.m. **DNA-PK inhibition resensitizes ovarian cancer cells to
cisplatin in vivo and is associated with modulation of AKT
pathway signaling***
Euan Stronach, Imperial College London, London, United
Kingdom
- 12:30 p.m.-2:00 p.m.** **Free Time/Lunch on Own**
- 2:00 p.m.-4:00 p.m.** **Session 3: High-Throughput Analysis in Ovarian Cancer**
*Session Chairperson: Sandra Orsulic, Cedars-Sinai Medical
Center, Los Angeles, CA*
- 2:00 p.m.-2:30 p.m. **Comprehensive proteomic analyses of TCGA ovarian cancer
specimens: Update from CPTAC**
Karin D. Rodland, Pacific Northwest National Laboratory,
Richland, WA
- 2:30 p.m.-3:00 p.m. **Functional genomics of ovarian cancer**
Gordon B. Mills, The University of Texas MD Anderson Cancer
Center, Houston, TX
- 3:00 p.m.-3:30 p.m. **Using publicly available databases for the functional
characterization of cancer genes**
Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA

*Short talks from proffered papers

3:30 p.m.-4:15 p.m. Keynote Address

Ovarian cancer: Time for a new paradigm
Robert F. Ozols, Fox Chase Cancer Center, Philadelphia, PA

4:30 p.m.-6:30 p.m. Poster Session A and Reception

Friday, September 20

7:00 a.m.-8:00 a.m. Continental Breakfast
Mentoring Roundtables

8:00 a.m.-10:00 a.m. Session 4: Therapeutic Opportunities from DNA Repair Deficiency
Session Chairperson: Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY

8:00 a.m.-8:30 a.m. **The Fanconi anemia-BRCA pathway and chemosensitivity of cancer cells**
Toshiyasu Taniguchi, Fred Hutchinson Cancer Research Center, Seattle, WA

8:30 a.m.-9:00 a.m. **Exploiting the translational and functional opportunities for homologous recombination deficiency**
Richard J. Edmondson, Newcastle University Medical School, Newcastle Upon Tyne, United Kingdom

9:00 a.m.-9:30 a.m. **PARP inhibitors in ovarian cancer: Clinical trial update**
Katherine Bell-McGuinn, Memorial Sloan-Kettering Cancer Center, New York, NY

9:30 a.m.-9:45 a.m. **In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer***
Mariam Al Hilli, Mayo Clinic, Rochester, MN

9:45 a.m.-10:00 a.m. **Ovarian cancers harbour defects in nonhomologous end joining resulting in error prone repair and resistance to rucaparib***
Aiste McCormick, Northern Institute for Cancer Research, Newcastle Upon Tyne, Tyne and Wear, United Kingdom

10:00 a.m.-10:30 a.m. Break

*Short talks from proffered papers

- 10:30 a.m.-12:30 p.m.** **Session 5: Targeting Drug Resistance**
Session Chairperson: David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada
- 10:30 a.m.-11:00 a.m. **Targeting acquired platinum resistance in ovarian cancer**
Hani Gabra, Imperial College London, London, United Kingdom
- 11:00 a.m.-11:30 a.m. **Targeting cancer stem cells to overcome chemotherapy resistance**
Ronald J. Buckanovich, University of Michigan, Ann Arbor, MI
- 11:30 a.m.-12:00 p.m. **Targeting the methylome for epigenetic resensitization of ovarian cancer**
Kenneth P. Nephew, Indiana University School of Medicine, Bloomington, IN
- 12:00 p.m.-12:15 p.m. **Targeting CD24+ ovarian cancer stem-like cells in a transgenic murine model of ovarian cancer restricts metastasis***
Daniela Burgos-Ojeda, University of Michigan, Ann Arbor, MI
- 12:15 p.m.-12:30 p.m. **HNF1beta confers resistance to oxidative stress of ovarian clear cell carcinoma***
Yasuaki Amano, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- 12:30 p.m.-2:30 p.m.** **Poster Session B and Lunch**

*Short talks from proffered papers

- 2:30 p.m.-4:30 p.m.** **Session 6: Clinical Implications of Intratumoral Heterogeneity**
Session Chairperson: Hani Gabra, Imperial College London, London, United Kingdom
- 2:30 p.m.-3:00 p.m. **Evolutionary dynamics of high-grade serous ovarian cancer genomes across anatomic space and time**
 Sohrab Shah, BC Cancer Agency Vancouver Centre, Vancouver, BC, Canada
- 3:00 p.m.-3:30 p.m. **Intratumoral heterogeneity and drug response in high-grade serous carcinoma**
 James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom
- 3:30 p.m.-4:00 p.m. **Analyzing the cellular basis for heterogeneity in serous ovarian carcinoma**
 Benjamin G. Neel, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada
- 4:00 p.m.-4:15 p.m. **Cellular heterogeneity of ovarian carcinoma cells and its impact on tumor behavior ***
 Suha Naffar-Abu Amara, Harvard Medical School, Boston, MA
- 4:15 p.m.-4:30 p.m. **Intra- and intertumor heterogeneity in epithelial ovarian cancer: Consequences for biomarker-dependent stratification of therapies***
 Rachel O'Donnell, Northern Gynaecological Oncology Centre, Gateshead, United Kingdom
- 4:30 p.m.-5:30 p.m.** **Panel Discussion: Survivorship Issues**
Sponsored by the Foundation for Women's Cancer
- Moderator :** Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY
- Panelists:**
- Cancer Survivors:**
 Patricia Goldman, Washington, DC
 Jennie McGihon, Alexandria, VA
- Physician Scientists:**
 David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada
 James D. Brenton, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

*Short talks from proffered papers

Saturday, September 21

- 7:00 a.m.-8:00 a.m.** **Continental Breakfast**
Mentoring Roundtables
- 8:00 a.m.-10:00 a.m.** **Session 7: Tumor Microenvironment**
Session Chairperson: Sandra Orsulic, Cedars-Sinai Medical Center, Los Angeles, CA
- 8:00 a.m.-8:30 a.m. **Causes and consequences of cancer-associated thrombocytosis**
Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX
- 8:30 a.m.-9:00 a.m. **Targeting the inflammatory cytokine network of serous ovarian cancer**
Frances R. Balkwill, Barts Cancer Institute, London, United Kingdom
- 9:00 a.m.-9:30 a.m. **Microenvironmental regulation of metastasis**
Ernst R. Lengyel, University of Chicago, Chicago, IL
- 9:30 a.m.-9:45 a.m. **Ovarian cancer cells activate the mesothelium in the peritoneal microenvironment promoting fibronectin production and the early steps of metastasis***
Hilary Kenny, University of Chicago, Chicago, IL
- 9:45 a.m.-10:00 a.m. **Immunomodulatory effects of 5-Azacytidine in ovarian cancer cell lines***
Katherine Chiappinelli, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University Medical School, Baltimore, MD
- 10:00 a.m.-10:15 a.m.** **Break**

- 10:15 a.m.-12:15 p.m.** **Session 8: Immunotherapy on the Horizon**
Session Chairperson: George Coukos, University Hospital of Lausanne, Epalinges, Switzerland
- 10:15 a.m.-10:45 a.m. **Immunotherapy opportunities and challenges in ovarian cancer**
George Coukos
- 10:45 a.m.-11:15 a.m. **Protective immune networks in ovarian cancer**
Brad Nelson, BC Cancer Agency, Vancouver Island, BC, Canada
- 11:15 a.m.-11:45 p.m. **NY-ESO-1 targeted immunotherapy**
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY
- 11:45 p.m.-12:15 p.m. **Combinatorial immunotherapy using whole tumor antigen: Evidence from phase I trials**
Lana E. Kandalaft, University of Pennsylvania School of Medicine, Philadelphia, PA
- 12:15 p.m.-12:30 p.m.** **Closing Remarks and Departure**